Step Forward for Lupus Research Across Ontario Join the WALK for Lupus Ontario — our...
Lupus Symptoms, Comorbidities and Major Organ Impacts In the last quarter, Lupus Ontario launched a...
Diagnosis Summary In the last quarter, Lupus Ontario launched a Patient Experience Survey to better...
On January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for the treatment of adult...
With this approval, pediatric patients aged five years and older with active lupus nephritis will...
The Canada Disability Benefit (CDB) is an important step forward to improving Canada’s social safety...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA)...
Lupus Ontario is excited to share share positive news of the Phase 3 REGENCY clinical...
